The Business Research Company’s report on the Primary Immunodeficiency Disorders Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the primary immunodeficiency disorders industry?
The growing prevalence of autoimmune diseases is expected to propel the growth of the primary immunodeficiency disorders market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells and tissues, treating them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is attributed to a complex interplay of environmental triggers, genetic predispositions, and lifestyle changes. Autoimmune diseases can cause primary immunodeficiency disorders by disrupting immune regulation and targeting immune cells, leading to weakened or dysfunctional immune responses. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based interactive online platform, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the primary immunodeficiency disorders market.
Access Your Free Sample of the Global Primary Immunodeficiency Disorders Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23483&type=smp
What is the estimated market size of the primary immunodeficiency disorders sector by 2029, based on current forecasts?
The primary immunodeficiency disorders market size has grown strongly in recent years. It will grow from $6.84 billion in 2024 to $7.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rising incidence of primary immunodeficiency disorders, increasing awareness among healthcare professionals, increasing demand for effective treatment, increasing research funding, and growing focus on pediatric care.
The primary immunodeficiency disorders market size is expected to see strong growth in the next few years. It will grow to $9.51 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing adoption of subcutaneous therapies, improving healthcare access, robust research and development, increasing high need for efficient treatments, and rising demand for immunoglobulin replacement therapy. Major trends in the forecast period include advancement in biotechnology, Innovative gene therapies and biologics, advancements in genetic testing and personalized medicine, advancements in gene therapy, and advancements in genetic tests.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23483&type=smp
Who are the top players in the primary immunodeficiency disorders market?
Major companies operating in the primary immunodeficiency disorders market are Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., Chengdu Rongsheng Pharmaceutical Co Ltd.
What are the major trends in the primary immunodeficiency disorders market?
Major companies operating in the primary immunodeficiency disorders market are focusing on developing advanced therapies such as intravenous immunoglobulin therapy to enhance patient outcomes by improving immune function. Intravenous immunoglobulin (IVIG) therapy is a treatment in which immunoglobulin (antibodies) derived from donor plasma is administered directly into a patient’s bloodstream via an IV. For instance, in June 2024, Grifols, a Spain-based healthcare company, received FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This newly developed, sugar-free, ready-to-use IgG solution is derived from human blood plasma and is intended for intravenous administration. Approved in the U.S. for substitution therapy in patients with primary antibody deficiency syndromes, Yimmugo provides antibody replacement to support individuals with immune system deficiencies. It enhances Grifols’ portfolio of plasma-based treatments by offering a safer and more effective option to help protect against infections.
Which geography holds the highest primary immunodeficiency disorders market share?
North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary immunodeficiency disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
How do different segments contribute to the overall expansion of the primary immunodeficiency disorders market?
The primary immunodeficiency disorders market covered in this report is segmented –
1) By Disease: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Other Diseases
2) By Treatment: Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell And Bone Marrow Transplantation, Gene Therapy, Other Treatments
3) By Diagnostic Type: Genetic Testing, Blood Testing, Flow Cytometry, Other Diagnostic Types
4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Research Institutions
Subsegments:
1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID), IgA Deficiency, IgG Subclass Deficiency, Specific Antibody Deficiency
2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID), T-Cell Deficiency, DiGeorge Syndrome, Wiskott-Aldrich Syndrome
3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD), Complement Deficiencies, Toll-like Receptor Deficiencies, Chediak-Higashi Syndrome
4) By Other Diseases: Hyper IgM Syndrome, Hyper IgE Syndrome, Ataxia-Telangiectasia, Combined Immunodeficiencies With Syndromic Features
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23483
What defines the structure and scope of the primary immunodeficiency disorders market?
Primary immunodeficiency disorders (PIDs) are inherited conditions that weaken or impair the immune system, increasing vulnerability to infections, autoimmune diseases, and certain cancers. Identifying and diagnosing primary immunodeficiency disorders early is crucial for timely treatment, infection prevention, and enhancing patient well-being through therapies such as immunoglobulin replacement or bone marrow transplants.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
